Nonclinical Efficacy and Toxicity and Selection of a Safe Clinical Starting Dose for an NMT Inhibitor in Development for Hematological Malignancies

达沙替尼 癌症研究 林恩 医学 药理学 细胞凋亡 肉豆蔻酰化 毒性 白血病 伊布替尼 淋巴瘤 髓系白血病 原癌基因酪氨酸蛋白激酶Src 生物 内科学 慢性淋巴细胞白血病 受体 磷酸化 生物化学 伊马替尼
作者
Michael J. Weickert,John E. Dillberger,Caren Brown,Francis Phaneuf,John R. Mackey,Randeep Sangha,Luc G. Berthiaume
出处
期刊:Blood [Elsevier BV]
卷期号:136 (Supplement 1): 40-41
标识
DOI:10.1182/blood-2020-141910
摘要

N-myristoylation is the addition of the 14-carbon fatty acid myristate to proteins. This plays a fundamental role in cell signaling: Over 500 proteins are myristoylated, including all 9 Src Family Kinases (SFK) Src, Lyn, Lck, Hck, and Fgr, as well as c-Abl, Gα subunits, caspase truncated (ct-) Bid and ct-PAK2, regulating cell growth and apoptosis. Human myristoylation is performed by two ubiquitously expressed N-myristoyltransferases NMT1 and NMT2. PCLX-001 is a new, orally bioavailable, small-molecule, dual NMT inhibitor under investigation as a novel and selective treatment for B-cell malignancies.In vitro, PCLX-001 inhibits the growth of hematological cancer cells at concentrations 10-fold lower than dasatinib and ibrutinib and prevents SFK recruitment to B cell receptor signaling complex, reducing survival signals and triggering apoptosis. PCLX-001 causes complete tumor regression in NOD/SCID mouse xenograft models of Acute Myeloid Leukemia (AML), Burkitt's Lymphoma (BL), and Diffuse Large B-cell Lymphoma (DLBCL), including drug-resistant human tumor in a PDX model. In mice, PCLX-001 produced complete remission of most xenografts at ≥35 mg/kg/day but also produced some deaths associated with bacterial infection and GI hemorrhage. In an AML xenograft mouse model, the drug exposure from oral dosing required to achieve 91% tumor inhibition was 3,423 ng*hr/mL (AUC (0-tlast)). When expressed on the basis of body surface area, the efficacious dose in mice was ≥105 mg/m2. To support clinical development, we evaluated PCLX-001 for safety in 4-week oral toxicity studies with 2-week recovery periods in rats at 50, 125, and 300 mg/kg/day and dogs at 2, 4, 8, and 12 mg/kg/day, performed to Good Laboratory Practice (GLP) standards. The highest non-severely toxic dose levels (HNSTDs) were 125 mg/kg/day for male rats, 300 mg/kg/day for female rats, and 4 mg/kg/day for dogs of both sexes. At higher dose levels, dose-limiting toxicity occurred within the first few days, was similar in both species, and was attributed to GI mucosal damage and decreased hematopoiesis, with secondary complications such as dehydration and inflammation. In dogs, systemic exposure to PCLX-001 increased more-than-proportionally with dose level after the first dose and did not change with repeated daily dosing. After the last dose at the HNSTD, Cmax averaged 651 ng/mL and 24-hour AUC averaged 3,760 h*ng/mL. In rats, systemic exposure to PCLX-001 after the first dose increased approximately proportionally with dose level and was much greater in males than females at all dose levels. With repeated daily dosing, exposure decreased dramatically in male rats but less so in female rats. As a result, exposure to PCLX-001 was similar in rats of both sexes after the last dose. After the last dose at the HNSTD in males and females, Cmax was 1650 and 8510 ng/mL, respectively, and 24-hour AUC averaged 6470 and 7590 h*ng/mL, respectively. When expressed on the basis of body surface area, the HNSTDs in male rats, female rats, and dogs were 750, 1800, and 80 mg/m2, respectively. As recommended in the ICH S9 Guidance, we chose a starting dose level of 20 mg/m2 for the first clinical trial because this was approximately 1/6th of the HNSTD in dogs. Given the dissimilarity of results between species, we compared the sequence of the NMTs in each since their inhibition was the target for PCLX-001. There was no significant difference between species in their sequence homology to humanNMT1(dog was 98%, rat 97% and mouse 99%), but dogNMT2had only 78% identity to humanNMT2while rat and mouseNMT2had 95% identity with humanNMT2. The significance of this dissimilarity is still under investigation. Disclosures Weickert: Pacylex Pharmaceuticals, Inc.:Current Employment, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees.Dillberger:Pacylex Pharmaceuticals, Inc.:Consultancy.Mackey:Pacylex Pharmaceuticals, Inc.:Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees.Berthiaume:Pacylex Pharmaceuticals, Inc.:Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青的应助被lancerimpp采纳,获得10
刚刚
Wray完成签到,获得积分10
刚刚
轻松的雨旋完成签到,获得积分10
刚刚
Guavazeal发布了新的文献求助10
刚刚
赘婿的应助被终有花开日采纳,获得10
刚刚
wzy发布了新的文献求助10
1秒前
1秒前
zzfplay完成签到,获得积分10
1秒前
1秒前
苦哈哈完成签到,获得积分10
1秒前
嘉浩完成签到,获得积分10
2秒前
kay发布了新的文献求助10
2秒前
Hayden完成签到,获得积分10
2秒前
FashionBoy的应助被yj采纳,获得10
2秒前
xifala完成签到,获得积分10
2秒前
zhangjoy完成签到,获得积分10
2秒前
2秒前
2秒前
长情冷菱完成签到,获得积分10
3秒前
黄油发布了新的文献求助10
3秒前
飘拂草完成签到,获得积分10
4秒前
ZZZ发布了新的文献求助10
4秒前
pjd666发布了新的文献求助10
4秒前
空空发布了新的文献求助10
4秒前
33完成签到 ,获得积分10
4秒前
kay完成签到,获得积分20
5秒前
More发布了新的文献求助10
5秒前
WanTo完成签到,获得积分10
5秒前
Medjay完成签到,获得积分10
5秒前
达不溜完成签到 ,获得积分10
6秒前
羽林完成签到,获得积分10
6秒前
冰雪关注了科研通微信公众号
6秒前
苏格拉丁发布了新的文献求助10
6秒前
6秒前
顾矜的应助被肖馨余采纳,获得30
6秒前
研友_VZG7GZ的应助被袁志阳采纳,获得10
6秒前
脑洞疼的应助被dxftx采纳,获得10
7秒前
7秒前
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315